[go: up one dir, main page]

MX2019004018A - Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. - Google Patents

Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.

Info

Publication number
MX2019004018A
MX2019004018A MX2019004018A MX2019004018A MX2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A
Authority
MX
Mexico
Prior art keywords
treatment
fiibrosis
cystic
substituted pyrrolidines
methods
Prior art date
Application number
MX2019004018A
Other languages
English (en)
Inventor
A Gfesser Gregory
J Scanio Marc
R Kym Philip
Bogdan Andrew
Liu Bo
Desroy Nicolas
R Koenig John
C Yeung Ming
J Altenbach Robert
N Greszler Stephen
De Lemos Elsa
Duthion Béranger
Gaëtan Housseman Christopher
Wang Xueqing
Couty Sylvain
Searle Xenia
Zhao Gang
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2019004018A publication Critical patent/MX2019004018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención desvela compuestos de formula (I) Ver formula: En donde R1, R2, R2A, R3, R3A, R4 Y R5 son como se definen en el presente documento. La presente invención se refiere a compuestos y su uso en el tratamiento de la fibrosis quística, métodos para su producción, composiciones farmacéuticas que los contienen y métodos de tratamiento de la fibrosis quística administrando un compuesto de la invención.
MX2019004018A 2016-10-07 2017-10-06 Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. MX2019004018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405598P 2016-10-07 2016-10-07
PCT/IB2017/056196 WO2018065962A1 (en) 2016-10-07 2017-10-06 Substituted pyrrolidines and their use in the treatment of cystic fiibrosis

Publications (1)

Publication Number Publication Date
MX2019004018A true MX2019004018A (es) 2019-11-12

Family

ID=60268420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004018A MX2019004018A (es) 2016-10-07 2017-10-06 Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.

Country Status (9)

Country Link
US (1) US9981910B2 (es)
EP (1) EP3523293B1 (es)
JP (1) JP2019537564A (es)
CN (1) CN110036009A (es)
AU (1) AU2017339249A1 (es)
BR (1) BR112019007039A2 (es)
CA (1) CA3039659A1 (es)
MX (1) MX2019004018A (es)
WO (1) WO2018065962A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JOP20200178A1 (ar) 2018-02-15 2022-10-30 Vertex Pharma حلقات ضخمة كمعدلات لمنظم توصيل التليف الكيسي عبر الغشاء، وتركيبات صيدلانية منها، واستخدامها في علاج التليف الكيسي، وعملية لتصنيعها
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20220089592A1 (en) 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
CA3150736A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Process of making cftr modulators
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Cystic fibrosis treatment methods
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939558B2 (en) 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
HUE032540T2 (en) 2004-06-24 2017-09-28 Vertex Pharma Modulators of ATP-binding cassette transporters
ES2548292T3 (es) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2009003009A1 (en) * 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
CN101925603B (zh) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
NZ592504A (en) 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
RS54369B1 (sr) 2010-10-08 2016-04-28 Nivalis Therapeutics, Inc. Nova jedinjenja hinolina supstituisana kao inhibitori s-nitrosoglutathione reduktaze
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
AU2012312520A1 (en) 2011-09-20 2014-05-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
WO2014180562A1 (en) * 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
US9133210B2 (en) * 2013-08-08 2015-09-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
EP3201265B9 (en) 2014-10-02 2022-05-04 Dow Global Technologies LLC High frequency weldable ethylene-based polymer compositions with good flame retardancy
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
HRP20201666T1 (hr) * 2014-10-31 2020-12-25 AbbVie Overseas S.à r.l. Supstituirani kromani i postupak njihove upotrebe
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TWI720032B (zh) 2015-10-09 2021-03-01 比利時商葛萊伯格有限公司 Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法
MX2018004364A (es) 2015-10-09 2018-08-16 Abbvie Sarl Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
US9873541B2 (en) 2015-12-24 2018-01-23 Connecticut Container Corp. Rapid assembling container

Also Published As

Publication number Publication date
AU2017339249A1 (en) 2019-05-02
CN110036009A (zh) 2019-07-19
BR112019007039A2 (pt) 2019-07-16
US20180099931A1 (en) 2018-04-12
EP3523293A1 (en) 2019-08-14
JP2019537564A (ja) 2019-12-26
WO2018065962A1 (en) 2018-04-12
EP3523293B1 (en) 2021-06-16
CA3039659A1 (en) 2018-04-12
US9981910B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
MX2019004018A (es) Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.
MX2019004019A (es) Pirrolidinas sustituidas como moduladores cftr.
PH12018502534A1 (en) Heteroaryl substituted pyridines and methods of use
PH12020500509A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
PH12017502201A1 (en) Substituted pyridines and method of use
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
NZ748946A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
SA518392049B1 (ar) مشتقات أمونيوم جديدة، عملية لتحضيرها وتركيبات صيدلانية تحتوي عليها
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
GEP20207058B (en) Imidazopyrazinones as pde1 inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
NZ735648A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12018501979B1 (en) Aminothiazole derivatives useful as antiviral agents
PH12018500378A1 (en) Novel annelated phenoxyacetamides
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.